Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Polyneuropathies Clear all
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Empasiprubart IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed No phase listed Observational

Immunoglobulin G Therapy Dose Optimization

NCT04818177
View directory record Official record
Conditions
Obesity, Immune Deficiency
Interventions
Institutional standard intravenous immune globulin treatment
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Treatment of Painful Diabetic Neuropathy With Photon Stimulation

NCT00539175
View directory record Official record
Conditions
Diabetic Neuropathy, Painful, Diabetic Neuralgia, Diabetic Polyneuropathy, Diabetic Mononeuropathy
Interventions
infrared light, infrared light; placebo
Device
Lead sponsor
East Bay Institute for Research and Education
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2007 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

NCT04929236
View directory record Official record
Conditions
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Panzyga
Drug
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Orange, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00507936
View directory record Official record
Conditions
Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
Interventions
ABT-894, placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jul 22, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

NCT07027111
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
NVG-2089
Drug
Lead sponsor
Nuvig Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Denton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

NCT00760955
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
TAK-583, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jul 22, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

NCT04584710
View directory record Official record
Conditions
Covid19
Interventions
RTB101, Placebo
Drug
Lead sponsor
Restorbio Inc.
Industry
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Farmington, Connecticut • Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jul 22, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04280718
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 1 Interventional

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

NCT06896188
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Retifanlimab, Chemotherapy, 9-ING-41
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418
View directory record Official record
Conditions
HR+/HER2-negative Breast Cancer
Interventions
TOS-358, Fulvestrant, Palbociclib, Ribociclib
Drug
Lead sponsor
Totus Medicines
Industry
Eligibility
18 Years and older · Female only
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Evaluating the Effect of Diabetes Control Through Intensive Lifestyle Modifications on Diabetic Peripheral Neuropathy

NCT01565317
View directory record Official record
Conditions
Diabetic Polyneuropathy, Weight Loss
Interventions
Weight Achievement and Intensive Treatment (Why WAIT)
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional Results available

Effect of Exercise and Surgical Weight Loss on Polyneuropathy

NCT03617185
View directory record Official record
Conditions
Polyneuropathies, Obesity, Bariatric Surgery Candidate
Interventions
High Intensity Interval Training (HIIT), Routine Exercise, Bariatric surgery
Other · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

NCT01545076
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Interventions
IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Phase 4 Interventional

D-Cycloserine for Serine Palmitoyltransferase Inhibition

NCT07542548
View directory record Official record
Conditions
Hereditary Spastic Paraplegia
Interventions
D-cycloserine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 6 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

NuroSleeve Powered Brace & Stimulation System to Restore Arm Function

NCT04798378
View directory record Official record
Conditions
Neurologic Diseases, Hemiparesis, Quadriplegia, Muscular Dystrophies, Arthrogryposis, Spinal Cord Injuries, Charcot-Marie-Tooth, Stroke, Weakness of Extremities as Sequela of Stroke, Weakness Due to Upper Motor Neuron Dysfunction, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Arm Paralysis, Cerebral Palsy
Interventions
Neurosleeve
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Wilmington, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 3 Interventional

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895
View directory record Official record
Conditions
Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Interventions
Acoramidis, Placebo oral tablet
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 75 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
39
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Completed No phase listed Observational

New Onset Weakness in Critically Ill Patients and the Risk of Death and Recurrent ICU Admission

NCT00106665
View directory record Official record
Conditions
Muscle Weakness, Critical Illness
Interventions
Not listed
Lead sponsor
Naeem Ali, MD
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Indianapolis, Indiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 22, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06798012
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-411
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
La Jolla, California • San Francisco, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

NCT01548573
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Tandem autologous stem cell transplant, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide, Bortezomib, Thalidomide, Melphalan
Drug · Procedure
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 22, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Driving Ability in Patients With CMT 1A

NCT02357355
View directory record Official record
Conditions
CMT 1A
Interventions
UIHC Driving Simulator
Device
Lead sponsor
Jerath U Nivedita
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 22, 2026, 2:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rapid Diagnostic Test for Detection of Group B Streptococcus in Pregnancy

NCT01445717
View directory record Official record
Conditions
Streptococcus Infection, Pregnancy
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jul 22, 2026, 2:06 AM EDT